Every article, report, and earnings note where CNC appears.
Centene is showing real margin-recovery progress after a difficult 2025, but Medicaid, Marketplace, and Medicare cost pressure still make this a Hold. Q1 2026 results and raised guidance support the turnaround, though the stock already trades near consensus value.
Health insurers are finally showing signs that the medical-cost spike is easing, but that is not the same thing as a clean, durable margin reset across the group. The better trade still looks selective: some operators are stabilizing, while others remain too expensive or too exposed to unresolved Medicare Advantage and Medicaid pressure.
Centene Corporation (CNC) climbs after a strong Q1 2026 earnings report lifted sentiment. The company raised full-year profit guidance, posted better-than-expected revenue and EPS, and showed improving medical cost control, signaling a possible margin recovery after a volatile stretch.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate CNC ReportCancel anytime